Last reviewed 2026-05-14 · How we verify

impact on VASP test

University Hospital, Brest · Phase 3 active Small molecule

impact on VASP test is a Small molecule drug developed by University Hospital, Brest. It is currently in Phase 3 development for Acute coronary syndrome.

This drug impacts the VASP test by affecting platelet function.

This drug impacts the VASP test by affecting platelet function. Used for Acute coronary syndrome.

Likelihood of approval

56.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Cardiovascular Phase 3 risk -2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	impact on VASP test
Sponsor	University Hospital, Brest
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 3

Mechanism of action

The exact mechanism of action is not well understood, but it is believed to involve modulation of platelet activation pathways.

Approved indications

Acute coronary syndrome

Common side effects

Thrombocytopenia

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

impact on VASP test CI brief — competitive landscape report
impact on VASP test updates RSS · CI watch RSS
University Hospital, Brest portfolio CI

Frequently asked questions about impact on VASP test

What is impact on VASP test?

impact on VASP test is a Small molecule drug developed by University Hospital, Brest, indicated for Acute coronary syndrome.

How does impact on VASP test work?

This drug impacts the VASP test by affecting platelet function.

What is impact on VASP test used for?

impact on VASP test is indicated for Acute coronary syndrome.

Who makes impact on VASP test?

impact on VASP test is developed by University Hospital, Brest (see full University Hospital, Brest pipeline at /company/university-hospital-brest).

What development phase is impact on VASP test in?

impact on VASP test is in Phase 3.

What are the side effects of impact on VASP test?

Common side effects of impact on VASP test include Thrombocytopenia.

Manufacturer: University Hospital, Brest — full pipeline
Therapeutic area: All drugs in Cardiovascular
Indication: Drugs for Acute coronary syndrome

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing